








.rlg t* P.r*,1+-# J BCRP JRAKI ;t* ;l-t^ .r* tlnrl ct' r.;4
AQ LrttJ*., JJl* 6Je ri: ;a ,-rKSi.;i g ou-1',J3,. 65143;ll t,
u "^lJ CL""' tL" "Jj
6)ti ,*,.,.- ;iS.l :t^l,ol; lll,..l






Kerrnan University Of Medical Sciences
Facualy of Medicine
In Partial Fulfilknent of the Requirements for the Degree
(MSC)
Title:
Relationship betrn'een IRAKI, BCRP and P-gp gene expression and drug










ri(:':r;v lJ/tilyto-/r,r$" dI atx
,L;l 
-L-l 
"j'-s.l,, il _-<a. j!,,) -..+ .;rl .',;1 -:J ,,r -L,- tp ;"_)*_L; .rh-_ ,lt,-:A.Ji




d--*." Jl; J'*i rL;- r, .r,-,.,.b i.9'.lo,J\--^rK. J,tu<" ;t *i- .rr5 e )f ;U'c-.-; ,J;ti; :--
ar-19 
.sl";t*t aS c*l os ;ai-; ,j;8 * i,.>,"..o .,--IATP (ABC) c-iJ a, a;ul9 .51-o c---::
4-Jtt";--l;1.!*o .ijiL 
.,. Lir GLy.jQ+;: 
'-c,l; 
tutb L (\IRAKs) \ #l*-' .-;-
ul3; 91y 9 c,L-S 9; 9;, .51-r9;ir di ...r"L^- alx* I P-gp ,BCRP , IRAK1 Ot* Olr" ,s*. L i . _-
,IRAK1/4 o-r-51\a (pg/pl) c-lj;Gic.oL-Siy. t ol6;xi.ill>*.5[,o c^Llc r;:l.l ei9r; :'.
*+ 
.5La --llo ,,-S iJRAK1/4 o-r;5;lqd (pg/pl) ;-tj ;ti-c s okyy.'-cl-a.. .5r.o 
- 
^-
,BT-549 ,BT-20-,MCF-7 JrL'.5Lr orl .5e.2 2, IRAKll4 "rrg )V (pglpl) c.l3 c^tl,c ,
WST-I ;>c,- S.;, o"lt )1o:li;l [ .r(!,r1;- .!ti ,+ aV-i &: C) ;r.ji t, J+ 3L .-.
.sL" ;j ,jl-? j-q^a .rrf ,lf ,r-rx:,,r V /7AAD- j*^(.;f ! ,"Jr- ,y_1 ,sr*i -(.i; . .- 
-
.n 
,-t,tt Real-Time PCR j9) U P-,ep ,BCFj
p 6-t-;5)t{d ;1 6'-;3.:tF ,r" J/- ".r rt+,t r" rr IC5s ,*ot5 c-.c! IRAKI o.r;5.s- :',a
,J.F 
'k 9BT-54991VICF-7 Jr.-.gLr o:r,r):-y'f {..,Kly s -61,Jy- u,-, : 
- 
-
l! J/-- .5Lo o:1 arL VY n,".-t?,il .-r,_.:f oroL,l-. MB-468 Jrl" or, ,.: IC5o 
-.*.:J .: ,-'
p; ) c-u.rl" Ji- .r{f,;-l c,-cL. u;-:; ,9L a,. ,:t*S 9y y- Lsk y..p cjb;.,': " Lr- . r
BT- 
.5Lo J*" .rt" o)t ,.S9sIRAK c<o'Xl,"t *V ,S or.ia) JLi aS :x.:rS 7A-\D
o:ulf;\." rb ;1 ; RT-qPCR Orjl e-L::.s!.r.tL, rtr MCI--7 e \IB--:. . :
,r-" ,;al_l VY 9 Yf ,\Y .5ta1L; ,,) .rL-t uA:- J|- o),r ,rQ? ,: 1, IRAK 9 ABCB , - --
i9- 
.r"i eb |'g" t+rt; ,il .i_ e".p ABCG3 -,l,r,g
9 JJi.rL-" Jr- c-r:-t;;u { 9 r1l,: ,r*< jL;r.r,-lrL<;Lr-: ,r^..i ,,51"s,"r: .: 
-- 
;.4




I lnterleukin Receptcrr,{s soc i i,.ted K irra se
.*.rB r-r=g
i=* *l,r-- .;..--+. u&-,5 c-.-E \ yy 
-;gs\:.a';:i 





61-o :*:-<-q: ji ;i;r 
-r^ a;.o- Al r; a-<..r.;;L ,r,L,,-. ,--"; ],* +;*;3orb turL ;;*>i _.1- .: -
"iol-< , -_-_t)'::.=-l-",,- ;_'il ;^q-t jLrl .r-+ g,1.,1 ;l-r.rl: ! ,J: ;t*l J;g-t Jfu\KI
..:r5 c.:li:rl )g gi .;: -
,.rKZy *>L3,;gn,;1:- ;lty ,u'-9sb ulb:ljl9 J
t.
Abstract
Background and objectives: Breast cancer is the most common type of cancer among
women. Chemotherapy is one of the main methods of breast cancer treatrnent, but this method
is increasingly affected due to drug resistance and the lack of resistance predictive factors.
One of the most important mechanisms of drug resistance in cancer is the activation of ATP-
binding cassette transporters (ABC). One of the newly discovered factors associated with drug
resistance in cancer cells is Interleukin Receptor Associated Kinase 1 (IRAKs). The aim of
this study was to investigate the relationship between IRAK1 expression amount, BCRP, P-gp
and sensitivity to the methotrexate and topotecan drugs.
Materials and methods: At various concentrations of topotecan and methotrexate, constant
concentration (lpglpl) of IRAKI/4 inhibitor, mixed various concentrations of topotecan and
constant concenffation (lpg/pl) of IRAK1/4 inhibitor, mixed various concentrations of
methotrexate and constant concentration (lpg/pl) of IRAK1/4 inhibitors on MCF-7, BT-20,
BT-549, MB-468 cell lines, the cell viability was examined by the trypan blue exclusion tes!
metabolic activity using colorimetric assay WST-I, and cell apoptosis by staining them with
Annexin-V/7AAD. The expression of IRAKI, BCRP, P-GP genes was also assessed by Real-
Time PCR method.
Results: IRAK1 inhibitor decreased ICso is the four cell lines. The least inhibitory effect on
increased drug sensitivity of methotrexate and topotecan was observed in the MCF-7 and BT-
549 cell lines, respectively; and the most inhibitory effect in reducing the IC50 was observed
in the MB-468 cell line. The 72-hour incubation of cell lines with IRAK inhibitors and
topotecan and methotrexate drugs significantly increased the annexin-V and annexin-
Y/7AAD positive cells, suggesting an apoptotic effect of IRAK on the BT-20, BT-549, MB-
468 and MCF-7 cell lines of breast cancer. RT-qPCR test results indicated that IRAK
inhibitor reduced the gene expression of ABCB1 and IRAK in four breast cancer cell lines at
12,24 and72 h time intervals, but had no effect on the expression of ABCG2 at any time.
Conclusion: Most chemotherapy drugs have a low therapeutic efficacy and rarely distinguish
between normal and malignant cells, a problem often reinforced by the onset of inevitable
resistance and relapse of the disease. Given the wide range of chemotherapy drugs that have a
P-gp substrate, it appears that selecting IRAK-I as a therapeutic target can be an effective
drug selection with cancer cell selection properties to reduce drug resistance to chemotherapy
agents. In this case, specific IRAK inhibitors can be used in combination with common
chemotherapy drugs to increase drug sensitivity and reduce the risk of tumor reclurence.
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